Finance entity
All 1 tracked stories fall under one category: earnings. Collegium Pharmaceutical is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Their average consequence score of 5 runs below the beat's 6 for that window. They are less corroborated than the beat average, carrying 2 original sources each against 2.6 for the same window.
Last mentioned: Feb 26, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: earnings. Collegium Pharmaceutical is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Their average consequence score of 5 runs below the beat's 6 for that window. They are less corroborated than the beat average, carrying 2 original sources each against 2.6 for the same window. We currently track 1 Finance story that mention Ironshore, all published on February 26, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 120 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Ironshore. Shared-story counts are live from our verified record — not editorial picks.
Wave Life Sciences and Collegium Pharmaceutical released their full-year 2025 financial results, highlighting a pivotal year for RNA therapeutics and specialty pain management. While Wave focuses on clinical milestones for its RNA editing platform, Collegium is driving growth through its commercial ADHD and pain portfolios.
Ironshore is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
